SYM has passed an unannounced check by Guangdong Food and Drug Administration (GDFDA) during 10 and 11 November 2015.

Today, SYM kicked off its strategic transition to a leading incubating business, with a new management team and an incubator focusing on neurosurgery and enhanced international cooperation. In doing so, SYM aims to meet the challenges brought by ever-evolving innovation and increasingly fierce competition in healthcare industry.